Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.52 |
| ▸ | RAD52 | P43351 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | CDK4 | P11802 | 2/20 | 0.48 |
| ▸ | CCND1 | P24385 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30162756 | 1.00 | LMNA (0.53) | LMNAMAPTMAPK1HTTGFER | |
| SCHEMBL24685193 | 0.88 | FDPS (0.50) | LMNAFGFR1KDM4EALDH1A1RCE1 | |
| SCHEMBL3938271 | 0.85 | TYK2 (0.54) | LMNAMAPTMAPK1HTTGFER | |
| SCHEMBL3937743 | 0.81 | TYK2 (0.51) | LMNAMAPTMAPK1HTTGFER | |
| SCHEMBL30162626 | 0.76 | ALDH1A1 (0.52) | LMNAMAPTMAPK1HTTGFER | |
| SCHEMBL21996574 | 0.76 | ALDH1A1 (0.52) | LMNAMAPTMAPK1HTTGFER | |
| SCHEMBL27319374 | 0.74 | GBA1 (0.49) | LMNAMAPTMAPK1HTTGFER | |
| SCHEMBL31534058 | 0.74 | GBA1 (0.49) | LMNAMAPTMAPK1HTTGFER | |
| SCHEMBL4066406 | 0.74 | LMNA (0.53) | LMNAMAPTMAPK1HTTGFER | |
| SCHEMBL6266725 | 0.73 | MAPT (0.49) | LMNAMAPTMAPK1HTTGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028680-A1 | EXPANSION OF NATURAL KILLER CELLS AND ILC3 CELLS WITH NOVEL AROMATIC COMPOUNDS | CELULARITY INC. (US) | 2023-01-26 | — | — | US | claimed |
| US-20220251104-A1 | AROMATIC COMPOUNDS FOR USE IN ACTIVATING HEMATOPOIETIC STEM AND PROGENITOR CELLS | CELULARITY INC. (US) | 2022-08-11 | — | — | US | claimed |
| EP-3887364-A1 | AROMATIC COMPOUNDS FOR USE IN ACTIVATING HEMATOPOIETIC STEM AND PROGENITOR CELLS | Celularity Inc. (US) | 2021-10-06 | — | — | EP | claimed |
| WO-2020113178-A1 | AROMATIC COMPOUNDS FOR USE IN ACTIVATING HEMATOPOIETIC STEM AND PROGENITOR CELLS | Celularity, Inc. (US) | 2020-06-04 | — | — | WO | claimed |
| US-20250295776-A1 | CLEAVAGE RESISTANT CD16 CONSTRUCTS AND USES THEREOF | CELULARITY INC. (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250276063-A1 | PLACENTA-DERVIED NK CELLS AS A SENOL YTIC FOR THERAPEUTIC AND OTHER USES | CELULARITY INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-20230355759-A1 | POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16 | CELULARITY INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230355759-A1 | POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16 | CELULARITY INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230355759-A1 | POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16 | CELULARITY INC. (US) | 2023-11-09 | — | — | US | disclosed |
| WO-2023010123-A1 | PLACENTA-DERVIED NK CELLS AS A SENOLYTIC FOR THERAPEUTIC AND OTHER USES | CELULARITY INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023010123-A1 | PLACENTA-DERVIED NK CELLS AS A SENOLYTIC FOR THERAPEUTIC AND OTHER USES | CELULARITY INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20230028680-A1 | EXPANSION OF NATURAL KILLER CELLS AND ILC3 CELLS WITH NOVEL AROMATIC COMPOUNDS | CELULARITY INC. (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2021022229-A1 | POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16 | CELULARITY INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2021022229-A1 | POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16 | CELULARITY INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2021016621-A1 | POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CD38 CHIMERIC ANTIGEN RECEPTOR | CELULARITY INC. (US) | 2021-01-28 | — | — | WO | disclosed |
| WO-2020252464-A1 | POPULATIONS OF NATURAL KILLER CELLS FOR TREATING CANCERS | CELULARITY INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252464-A1 | POPULATIONS OF NATURAL KILLER CELLS FOR TREATING CANCERS | CELULARITY INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020113178-A1 | AROMATIC COMPOUNDS FOR USE IN ACTIVATING HEMATOPOIETIC STEM AND PROGENITOR CELLS | Celularity, Inc. (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020113182-A1 | EXPANSION OF NATURAL KILLER CELLS AND ILC3 CELLS WITH NOVEL AROMATIC COMPOUNDS | Celularity, Inc. (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020113182-A1 | EXPANSION OF NATURAL KILLER CELLS AND ILC3 CELLS WITH NOVEL AROMATIC COMPOUNDS | Celularity, Inc. (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295776-A1 | CLEAVAGE RESISTANT CD16 CONSTRUCTS AND USES THEREOF | PBK, PIGK, CD74 | LMNA 742/4885MAPT 4275/4885MAPK1 3371/4885 |
| US-20230355759-A1 | POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16 | PBK, KLKB1, PIGK | LMNA 478/4885MAPT 4385/4885MAPK1 4645/4885 |
| US-20230028680-A1 | EXPANSION OF NATURAL KILLER CELLS AND ILC3 CELLS WITH NOVEL AROMATIC COMPOUNDS | PBK, ILF3, NFATC1 | LMNA 1598/4885MAPT 4225/4885MAPK1 2133/4885 |
| US-20220251104-A1 | AROMATIC COMPOUNDS FOR USE IN ACTIVATING HEMATOPOIETIC STEM AND PROGENITOR CELLS | ALPP, MCL1, NFATC1 | LMNA 3390/4885MAPT 4444/4885MAPK1 2857/4885 |
| US-20250276063-A1 | PLACENTA-DERVIED NK CELLS AS A SENOL YTIC FOR THERAPEUTIC AND OTHER USES | PBK, CD47, GZMB | LMNA 1170/4885MAPT 3342/4885MAPK1 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.